Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors.

CONCLUSION: EPx4 is highly effective and well-tolerated in patients with good-risk GCT, and remains a standard of care.
IMPLICATIONS FOR PRACTICE: EPx4 is a standard-of-care regimen for all patients with good-risk GCT with a favorable response rate and disease-specific survival of 98%. Full-dose administration of etoposide and cisplatin and complete resection of residual disease lead to optimal outcomes. EPx4 should be the recommended regimen in active smokers, patients with reduced or borderline kidney function, and patients over age 50, which are patient groups at increased risk for bleomycin pulmonary toxicity. Due to a risk of acquired severe pulmonary illness, EPx4 may also be favored for patients who vape or use e-cigarettes, and during ongoing transmission of SARS-CoV-2.
PMID: 33586274 [PubMed - as supplied by publisher]

Source: The Oncologist - February 14, 2021 Category: Cancer & Oncology Authors: Funt SA, McHugh DJ, Tsai S, Knezevic A, O'Donnell D, Patil S, Silber D, Bromberg M, Maryann Carousso NP, Reuter VE, Carver BS, Sheinfeld J, Motzer RJ, Bajorin DF, Bosl GJ, Feldman DR Tags: Oncologist Source Type: research